Infections remain common life-threatening complications of bone marrow transplantation. To examine clinical factors that affect infection risk, we retrospectively studied patients who received bone marrow transplants (53 autologous and 51 allogeneic). Over a median of 27 hospital days, 44 patients developed documented infections. Both autologous transplantation and hematopoietic growth factor use were associated with less prolonged neutropenia and decreased occurrence of infection (P £ .05). In a survival regression model, variables independently associated with infection risk were the log 10 of the neutrophil count (hazard ratio Bone marrow transplantation is increasingly used to treat infection during this early period [2] , and use of antibiotics may reduce this risk [6, 7]. However, studies have not quantitatively malignant and nonmalignant diseases. Approximately 30,000 transplantations were performed worldwide in 1995 [1] . Bone examined the relationship between neutrophil count, use of antimicrobial agents, and infection risk in the setting of transmarrow transplantation cures many patients of their underlying disease but is itself associated with substantial morbidity and plantation or other currently used intensive treatment regimens.
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Other potential risk factors arising in the immediate posttransmortality.
Infection is among the most common life-threatening complantation period, such as mucositis [8] or the use of corticosteroids [9] , have been associated with infection in individual plications of bone marrow transplantation. Although persisting deficits in both cellular and humoral immunity increase infecstudies, but their effects have not been clearly delineated.
To improve the understanding of determinants of infection tion risk for months following transplantation [2] , one-half of all infectious complications occur early in the first 4 -6 weeks risk for transplant recipients, we retrospectively studied infectious complications in our transplantation unit. We particularly following bone marrow grafting [3] . During the early posttransplantation period, up to 71% of transplant recipients develop focused on characterizing how infection risk is related to neutrophil count and use of oral and intravenous antibiotics. To documented infections [4] , some of which may be fatal [3, 5] .
Despite a qualitative understanding of risk factors for infecour knowledge, this study of 104 patients represents the largest reported study examining infection risk for both autologous tion in the weeks immediately following transplantation, a more quantitative assessment of these risk factors has been lacking. and allogeneic transplant patients. Neutropenia, a direct result of the myeloablative transplantation Patients and Methods regimens, is almost certainly the predominant risk factor for
Patients
We retrospectively reviewed hospital records of all adult patients who underwent bone marrow transplantation at New busulfan [10] . Patients with relapsed, refractory, or secondary õ500/mm 3 were present. Regimens typically included imipenem or ceftazidime, and vancomycin was added for treatment leukemia received etoposide in addition to one of these regimens [11] . Patients with chronic myelocytic leukemia received of suspected infection due to gram-positive bacteria. Occasionally, intravenous antibiotics were added to continuing prophysplenic irradiation prior to conditioning, and patients with aplastic anemia received total lymphoid irradiation instead of laxis with ciprofloxacin, such as vancomycin for treatment of suspected catheter infection. Patients with persistent unextotal body irradiation [12] . Most patients with multiple myeloma were treated with melphalan and total body irradiation plained fever were evaluated daily, and antibiotic regimens were modified according to clinical evidence and microbiologias the preparative regimen for either autologous or allogeneic transplantation [13] .
cal test results. Amphotericin B treatment was added empirically after 3 -5 days of unexplained fever. Patients with lymphoma or breast carcinoma who were undergoing autologous stem cell transplantation were treated with carboplatin, cyclophosphamide, and etoposide with or without All patients undergoing allogeneic transplantation received For each hospital day, we recorded the patient's maximum temperature and absolute neutrophil count. We noted start and continuous infusion of cyclosporine as prophylaxis for graftversus-host disease on days 01 to 50; doses were adjusted to stop dates for ciprofloxacin and fluconazole prophylaxis and treatment with intravenous antibiotics, cyclosporine, and cortimaintain serum levels of 475 -525 ng/mL. Therapy was switched to oral cyclosporine on day 50. Allogeneic transplant costeroids. We recorded the grade of oral mucositis and acute graft-versus-host disease (none, mild, moderate, or severe) as recipients also received methotrexate (15 mg/m 2 intravenously on day 1 and 10 mg/m 2 intravenously on days 3 and 6; the last described in physicians' daily notes [18, 19] . For the 24% of days on which the grade of mucositis was unavailable, we used dose was omitted for patients with severe mucositis). Patients with moderate or severe graft-versus-host disease, despite prothe grade at the last entry.
We noted the occurrence of all documented infections [20] . phylaxis, were treated with intravenous methylprednisolone (20 -200 mg/d).
For each infection, we required an oral temperature of at least 38ЊC and microbiological or clinical documentation in the medStarting before day 03, patients routinely received ciprofloxacin (500 mg orally q12h) as prophylaxis for infection.
ical record. We used prospectively defined criteria, based on recommendations of the Immunocompromised Host Society, Acyclovir prophylaxis (200 mg orally five times daily or 5 mg/kg intravenously q8h) was initiated on day 01 and continto identify infections [20] . For microbiological documentation, we required positive cultures of a specimen from the site, such ued until engraftment. To minimize risk of invasive fungal infections, all patients received oral clotrimazole, nystatin, or as a positive culture of a catheter tip (ú15 cfu) or a positive urine culture (ú100,000 cfu/mL). Clostridium difficile colitis fluconazole and stayed in high-efficiency particulate air -filtered rooms. Most patients undergoing autologous transplantawas documented in the setting of diarrhea and a stool test positive for toxin. Isolated bacteremia or fungemia was defined tion received either granulocyte colony-stimulating factor (5 mg/[kgrd], 43 patients) or granulocyte-macrophage colonyby at least one positive blood culture (or two cultures positive for coagulase-negative staphylococci). stimulating factor (5 -10 mg/[kgrd], two patients) from day 0 until their neutrophil count was ú11,000/mm 3 for three consecFor clinical documentation, in the absence of positive cultures, we required evidence of local infection, such as an abnorutive days. Following engraftment, patients receiving allogeneic transplants and patients with lymphoma began prophylaxis mal chest radiograph or evidence of catheter tunnel infection, that was described by clinicians in the medical record. Fever for Pneumocystis carinii pneumonia with either inhaled pentamidine or oral trimethoprim-sulfamethoxazole. In addition, alone was not sufficient evidence for the presence of infection. Specimens for bacterial surveillance cultures were not routinely following engraftment, ganciclovir therapy (5 mg/kg intravenously five times per week) was given to patients who were obtained.
For bacteremias and fungemias, we defined the day of onset seropositive for cytomegalovirus or who received grafts from seropositive donors. Patients undergoing allogeneic transas the day on which the specimen for the first positive culture was obtained from the patient. For other infections, the day of plantation received eight weekly infusions of intravenous immune globulin (0.5 g/kg), the dose of which was subsequently onset was the day on which symptoms first developed, as viewed in retrospect, even if clinicians did not diagnose infectapered.
Intravenous antibiotic therapy was started empirically at clition on that day. For example, for colitis, the day of onset was the day that diarrhea developed. If the only symptom was fever nicians' discretion if fever was present (oral temperature, ú38ЊC) and routinely if fever and a neutrophil count of (as for some microbiologically documented catheter infec- . Before analysis, we catevariables) and against ranked failure times (to test the proporgorized underlying diagnoses into four groups on the basis of tional hazards assumption) [31] . the intensity of pretreatment and transplantation protocols. In
To illustrate further how antibiotic use affects the infection order of decreasing intensity, the groups were as follows: acute risk that arises from neutropenia, we developed several hypomyelogenous leukemia, acute lymphocytic leukemia, and mythetical curves depicting the time to first infection for patients elodysplastic syndrome; chronic lymphocytic leukemia, multimanaged with different patterns of antibiotic use. To do this, ple myeloma, and lymphoma; chronic myelocytic leukemia and we applied our multivariate survival model to the baseline aplastic anemia; and breast carcinoma.
hazard function, thereby creating predicted survival curves for Patient characteristics were compared between groups by these patterns of antibiotic use [31] . We developed these curves using the x 2 test for categorical data, the t test or Wilcoxon for patients undergoing allogeneic transplantation; the mean rank-sum test for continuous data, and the logrank test for value of the logarithm of the neutrophil count for each transcensored data [21] . We tested for trends across categories by plantation day in our cohort was used to model these curves. means of the rank ordering of categories as a continuous variStatistical calculations were performed with use of S-PLUS able in regression models [22, 23] .
(Version 3.3, MathSoft, Seattle) and SAS (Version 6.12, SAS The effect of variables that change over time, or that alter Institute, Cary, NC). A level of 5% was used to determine the time to an outcome without affecting the overall proportion statistical significance. of patients with the outcome, may be difficult to evaluate with data summarized at the level of the individual patient [24, 25] . Therefore, in exploratory analyses of risk factors for infection, Results we divided patients' courses into separate patient-days and analyzed infection risk with the patient-day as the unit of analyPatients sis. By dividing patients' courses into multiple independent periods, we derived estimates for infection risk that correspond
The 104 patients included in this study are described in table to rates (events per patient-day) for different levels of variables 1. One patient with acute myelogenous leukemia received two of interest: neutrophil count, ciprofloxacin prophylaxis, intravetransplants (one autologous transplant followed by a matched nous antibiotic therapy (started empirically before documented unrelated donor transplant after relapse) and is included twice. infection), and change of neutrophil count. To avoid potential Approximately one-half of the patients received autologous confounding by patient factors that change after infection has transplants, and about one-half received allogeneic transplants. occurred, in these analyses of infection risk, we censored all
The mean age of patients was 39 years, with a tendency for data after documented first infections.
those receiving allogeneic transplants to be younger. Patients As an extension of exploratory analyses, we constructed receiving allogeneic transplants were more likely than autoloproportional hazards survival models, incorporating time-varygous transplant recipients to have diagnoses associated with an ing covariates, for the time to first infection [23] . In univariate intensive pretreatment or transplantation protocol (P Å .03). models, we examined separately the effect of each covariate, Ciprofloxacin prophylaxis was administered to 72% of pasuch as neutrophil count, corticosteroid use, or mucositis. In tients. When noted, reasons for not receiving prophylaxis inthe multivariate model, we focused on the effects of neutrophil cluded inability to take oral medications (12 patients), preexcount and antibiotic use, since our exploratory analyses and isting receipt of intravenous antibiotics (10), or allergy to work by other investigators [26 -30] suggested that these were quinolones (1). Eighty-five percent of autograft recipients rehighly related to infection risk.
ceived hematopoietic growth factors, compared with only 4% Several important model characteristics were shaped by our of allograft recipients; the duration of both moderate and severe exploratory analyses. As risk for infection was less correlated neutropenia was significantly shorter for autograft recipients with the neutrophil count than with the logarithm of the neutrothan for allograft recipients. Allogeneic transplant recipients phil count, we used the log 10 of the neutrophil count for the had longer hospital stays than autologous transplant recipients. proportional hazards models; with neutrophil counts of Six deaths, all due to multiorgan failure, occurred in allogeneic õ5/mm † With the exclusion of patients with breast cancer, the difference in gender was no longer significant (P Å .12). ‡ P value for trend across four diagnostic groups ordered by treatment intensity.
Infectious Complications
tropenia (mean duration: 7 vs. 11 days; P Å .05) and developed fewer infections (22% vs. 75%; P Å .003). Thirty-six allogeDuring their hospital course, 102 patients (98%) had at least neic transplant recipients received irradiation as part of their one temperature measurement of §38ЊC, and 103 (99%) received conditioning regimen; these patients were as likely to develop intravenous antibiotic therapy. The maximum daily temperature infections as the 15 patients who did not receive irradiation was §38ЊC on 1,001 (32%) of 3,118 total patient-days.
(50% vs. 67%, respectively; P Å .43). Fifty-five documented infections occurred in 44 patients (taNine patients developed 10 separate infections due to Canble 2). Thirty-four patients had 1 infection each, 9 had 2 infecdida species (table 2) . None of these patients received fluconations, and 1 had 3 infections. The overall infection rate was zole prophylaxis, compared with 10 of 95 patients who did not 18 per 1,000 patient-days. The median day of onset for first develop fungal infections (P Å .61). Four percent of autologous infections was day 6, and that for subsequent infections was transplant recipients developed candidal infections, compared day 12; six infections occurred on or before transplant day 0.
with 14% of allogeneic transplant recipients (P Å .15). There Four (9%) of 44 patients with infection died, and infection may were no infections caused by Aspergillus species or cytomegahave contributed to three of these deaths.
lovirus during this early posttransplantation period. Allogeneic transplant recipients were more likely than autol- neutrophil count of §100/mm 3 (P Å .32). of 10, infection risk is reduced by 30% (95% CI, 0 -52% ‡ Three catheter infections caused by E. cloacae, S. maltophilia, and C. guillermondii were implicated as possibly contributing to death. relative reduction). Less significantly related to infection risk § Catheter infections due to C. parapsilosis and E. faecalis and due to Serwere patient age, ciprofloxacin prophylaxis, and mucositis. ratia marcescens, S. aureus, and viridans streptococci.
Staphylococcus aureus
1 1 0 Gram-negative bacteria Enterobacter cloacae 1 0 1 ‡
Proportional Hazards Models for Infection Risk
In the multivariate proportional hazards model, the logarithm 10 of neutrophil count, use of ciprofloxacin, and use of intravenous antibiotics for §2 days all remained negatively associated with infection risk (table 4 ). An interaction term patients were receiving ciprofloxacin prophylaxis or empirical intravenous antibiotic therapy for fever. When the neutrophil between the log 10 of neutrophil count and use of intravenous antibiotics for §2 days was also significant. The effect of this count was §500/mm 3 , the risk of developing documented infection was õ15 per 1,000 patient-days, regardless of antibiotic interaction term on infection risk can be appreciated from figure 2, which graphically displays the hazard ratios calculated from use. For patients not receiving prophylaxis or intravenous antibiotic therapy, the rate of infection increased dramatically as this multivariate model. For patients receiving no antibiotic therapy, infection risk increases steeply at low neutrophil the neutrophil count declined to 71 per 1,000 patient-days with moderate neutropenia (neutrophil count, 100 -499/mm 3 ) and to counts; however, for patients receiving intravenous antibiotic / 9c61$$fe13 01-20-99 06:26:38 cida UC: CID therapy, infection risk increases less dramatically. These calcuand Stenotrophomonas maltophilia) were resistant to quinolones; both occurred in patients who had received ciprofloxacin lated hazard ratios parallel the depiction of infection risk displayed in figure 1 .
prophylaxis. One reason that ciprofloxacin prophylaxis did not result in When added to the multivariate model, none of the remaining variables in table 3 was significantly associated with infection more substantial overall benefits may be that patients who started prophylaxis actually received ciprofloxacin on only 708 risk, except amphotericin B use (adjusted HR, 2.40; 95% CI, 1.10 -5.22). In addition, rate of change of the neutrophil count (42%) of 1,677 patient-days that they were at risk for first infection. Twenty-eight patients stopped prophylaxis because was not significantly associated with infection risk.
of vomiting or mucositis and did not immediately begin intravenous antibiotic therapy (median day on which prophylaxis was
Ciprofloxacin Prophylaxis
stopped, day 0). These patients subsequently had 11 infections in 280 patient-days (39 per 1,000 patient-days). For days when Although the multivariate survival regression model demonstrates that receipt of ciprofloxacin prophylaxis on any given these patients also had moderate or severe neutropenia, there were nine infections in 74 patient-days (122 per 1,000 patientday was associated with a decreased risk for developing first infection, patients for whom ciprofloxacin prophylaxis was days).
To clarify further the effect of antibiotic use on infection started were as likely to develop a documented infection as patients who never received prophylaxis (32 of 75 vs. 12 of risk, we derived curves predicting time to first infection that were based on the multivariate survival model. The occurrence 29, respectively; P Å .91). Moreover, receiving any prophylaxis did not delay first infection (P Å .84). Three of the five of infection in the first month following allogeneic transplantation according to three possible patterns of antibiotic use is infections due to gram-negative bacteria occurred in patients who had received ciprofloxacin prophylaxis. Two infections shown in figure 3 . Of patients who start ciprofloxacin prophylaxis and are able to continue it until their neutrophil counts due to gram-negative bacteria (caused by Enterobacter cloacae / 9c61$$fe13 01-20-99 06:26:38 cida UC: CID and to a survival analysis [25] , which are particularly important relatively small when the neutrophil count was ú500/mm neutropenia and infection risk has long been noted, our study * P value for linear trend across four diagnostic groups.
is the first to describe this relationship in a quantitative manner for patient subgroups clearly defined by antibiotic use. For patients receiving no antibiotics, rates of infection associated return to ú500/mm 3 , 70% will develop infection. Because with moderate or severe neutropenia were 71 per 1,000 patientvomiting or mucositis may prevent some patients from continudays and 110 per 1,000 patient-days, respectively. In an earlier ing oral prophylaxis, we also examined infection risk for those study of patients with acute leukemia, Bodey and co-workers stopping prophylaxis on day 0. Of patients receiving no antibi- [26] reported somewhat lower infection rates of 20 per 1,000 otic therapy after day 0, 87% will develop infection by day patient-days and 42 per 1,000 patient-days for corresponding 30. However, of patients for whom ciprofloxacin prophylaxis is switched to intravenous antibiotic therapy on day 0, only 59% will develop infection by day 30. Corresponding rates of degrees of neutropenia. However, this previous study did not
The incidence of early infections was substantially higher among allogeneic transplant recipients (55%) than among aureport infection rates separately for patients receiving and not receiving antibiotic therapy, and patients in the previous study tologous transplant recipients (30%); these figures are consistent with those in other recent reports [4, 5, 32] . The cause were less intensely treated than patients treated with current transplantation regimens. For patients not receiving antibiotic for the high infection risk for patients receiving allogeneic transplants is likely multifactorial. It derives in large part from therapy, our multivariate survival model predicts a 24% relative increase in infection risk with each halving of the neutrophil their prolonged and severe neutropenia: in the present study, allogeneic transplant recipients had a neutrophil count of count and a doubling of infection risk with each decrease of the neutrophil count by a factor of 10. õ100/mm 3 for an average of 15 days compared with 8 days / 9c61$$fe13 01-20-99 06:26:38 cida UC: CID for autologous transplant recipients. Severe mucositis and imtherapy eliminates the steep relationship between neutrophil count and infection risk (figure 2). For example, for patients munosuppressive medications used in allogeneic transplantation might also contribute to the high infection risk seen for receiving intravenous antibiotic therapy, the infection risk when the neutrophil count is 100/mm 3 is predicted to be only 6% these patients. However, our survival regression models demonstrated no increased daily risk associated with these factors, higher than when the neutrophil count is 500/mm 3 . We also observed a 58% reduction in the risk for developing thereby suggesting that it is indeed a more prolonged period of risk (due to neutropenia) that accounts for most of the increased infection on days when patients received prophylaxis with ciprofloxacin, an oral quinolone with a broad antibacterial specinfection risk for allogeneic transplant recipients.
Further evidence in the present study that neutropenia is an trum. However, although our study documents that patients benefit from ciprofloxacin prophylaxis on days when it is actuimportant risk factor for infection is provided by the observation that, for autologous transplant recipients, use of hematopoially administered, patients receiving any prophylaxis were just as likely eventually to develop infection as were patients who etic growth factors (in particular, granulocyte colony-stimulating factor) was associated with less prolonged neutropenia and never received prophylaxis. This apparent contradiction is explained by our observation that over one-third of patients who fewer infections. Granulocyte colony-stimulating factor causes the proliferation and differentiation of marrow progenitors that started ciprofloxacin prophylaxis later stopped it because of severe mucositis or vomiting, and on days when these patients form mature neutrophils [33] . Our results are consistent with results from clinical trials showing that use of granulocyte were also neutropenic, they were at very high risk for infection. Because intensively treated patients may be unable to comply colony-stimulating factor shortens the duration of neutropenia following autologous bone marrow or stem cell transplantation with an oral prophylaxis regimen, quinolone prophylaxis may not actually affect the time to infection or the overall proportion [34 -36] .
It is sometimes stated that a falling neutrophil count is a risk of patients eventually infected. Our analysis suggests that for those patients for whom ciprofloxacin prophylaxis is started factor for infection, independent of the level of neutropenia itself [37, 38] , but we found no evidence that infection risk who later cannot tolerate it, a switch to intravenous antibiotic therapy (which provides dramatic protection during periods of was related to the rate of change of the neutrophil count. Two previous studies described substantial proportions of infections severe neutropenia) may result in fewer documented infections than no subsequent prophylaxis (figure 3). preceded by falling neutrophil counts [26, 39] . However, these studies did not report comparable control data for periods withPart of the limited overall effectiveness of quinolone prophylaxis in the current study may also be due to the high proportion out infection; therefore, it is impossible to identify a risk for infection that is associated independently with a decline in of infections caused by gram-positive bacteria, even in those patients not receiving prophylaxis. Quinolone prophylaxis is neutrophil counts. In vitro studies demonstrate that neutrophil function is frequently abnormal following both intensive chelargely ineffective in preventing these infections [46] . Prophylaxis does prevent infections due to gram-negative bacteria in motherapy (when neutrophil counts decline) and marrow engraftment (when neutrophil counts rise again) [40, 41] , and our neutropenic patients with cancer [27 -30, 46 ], but infections due to gram-negative bacteria are increasingly uncommon [7] ; results are consistent with a diminished level of neutrophil function that remains relatively constant throughout the periin the present study, they represented õ10% of infections. Perhaps most worrisome is that two of three infections due to transplantation period.
For neutropenic patients with fever, the administration of gram-negative bacteria in ciprofloxacin recipients in this study were resistant to quinolones. We and other researchers have empirically chosen intravenous antibiotics is a widely accepted clinical practice [6, 7] . Prompt empirical use of antibiotics expressed concern regarding the emergence of quinolone resistance with its continued use as prophylaxis for patients with reduces mortality due to occult life-threatening infections that may already be present at the time of the first fever [42] .
neutropenia [6, 46] . Benefits from quinolone prophylaxis may be even smaller Clinicians usually continue empirical antibiotic therapy until neutropenia resolves, even without documented infection, than our observations suggest, because in this study healthier patients were able to comply with this oral regimen and sicker largely because of findings from two trials that showed high rates of infection after premature discontinuation of antibiotic patients (who are more likely to develop infections) were switched from prophylaxis to intravenous antibiotic therapy. therapy [43, 44] .
In the present study, we found that empirically administered In any event, our finding that ciprofloxacin prophylaxis may not decrease the overall proportion of patients infected differs antibiotics may actually prevent subsequent infections in febrile patients. After empirical intravenous antibiotic therapy was from results of some of the randomized trials of quinolone prophylaxis [27, 47] . This discrepancy may be related to the started, the risk of developing a documented infection was õ25 per 1,000 patient-days, regardless of the level of neutropenia increasing quinolone resistance among colonizing organisms, particulars of our patient population, or other undetermined ( figure 1 The emergence of antibiotic resistance associated with antibiotic use for bone marrow transplant recipients is also an quinolone prophylaxis should be routinely administered [6] .
It might be expected that mucositis and the use of immunoarea that needs continued attention. suppressive medications (such as cyclosporine and corticosteroids) increase infection risk substantially, but we did not ob-domized trials and cost-benefit analyses for particular strate-/ 9c61$$fe13 01-20-99 06:26:38 cida UC: CID
